Skip to content
Inciteful Med

The Genetics of Angelman Syndrome: UBE3A, Subtypes, and Your Diagnosis

Last updated:

Angelman syndrome occurs when the maternal UBE3A gene is missing or broken. Because the paternal copy is naturally silenced in the brain, no active UBE3A protein is produced. DNA testing identifies the child's specific genetic subtype, which helps doctors predict symptom severity and guide care.

Key Takeaways

  • • Angelman syndrome is caused by a lack of functioning UBE3A protein in the brain due to issues with the maternal copy of the gene.
  • • There are four genetic subtypes of Angelman syndrome, with maternal deletion being the most common and typically causing the most severe symptoms.
  • • The diagnostic process usually requires a combination of DNA methylation testing and UBE3A gene sequencing.
  • • An EEG showing a unique high-amplitude 'delta wave' pattern is a strong biomarker used to support an Angelman syndrome diagnosis.
  • • Emerging therapies like Antisense Oligonucleotides (ASOs) aim to treat the condition by 'unsilencing' the paternal copy of the UBE3A gene.

Genetic testing provides more than just a name for your child’s condition; it offers a precise map of the underlying biology. Understanding the “how” and “why” behind Angelman syndrome (AS) can help you navigate treatments, participate in research, and better understand your child’s unique needs [1].

The Biology: UBE3A and Genomic Imprinting

To understand AS, we have to look at a process called genomic imprinting [2]. Typically, we inherit two copies of every gene—one from our mother and one from our father. However, in certain parts of the brain, nature “silences” the father’s copy of a gene called UBE3A [3]. This means the brain relies entirely on the mother’s copy to produce the UBE3A protein, which is essential for healthy brain development [2][4].

The father’s copy is silenced by a “blocker” called the UBE3A-ATS (Antisense Transcript) [4][5]. In children with Angelman syndrome, the mother’s copy of the gene is either missing or broken. Because the father’s copy is already silenced, the brain ends up with no active UBE3A protein at all [3].

The Four Genetic Subtypes

The “subtype” of AS refers to exactly why the maternal UBE3A gene isn’t working. These subtypes can influence the severity of symptoms [6][7].

Genetic Subtype Prevalence Description General Clinical Impact
Maternal Deletion ~75–80% A piece of chromosome 15 containing the UBE3A gene is missing. Most severe form. Associated with significant motor challenges, higher risk of microcephaly, and more complex epilepsy [8][6].
UBE3A Mutation ~10–20% The gene is present but contains a mutation (“typo”) preventing it from functioning. Slightly milder symptoms. Often associated with better communication skills and fewer seizures [8][9].
Paternal Uniparental Disomy (UPD) ~3–5% Child inherits two copies of chromosome 15 from the father and none from the mother. Milder presentation. Often results in better physical growth and a lower likelihood of early-onset seizures [9][10].
Imprinting Defect ~2–3% Gene is present, but the “switch” to turn on the mother’s copy is set to “off”. Can lead to an “atypical” presentation, sometimes allowing for limited speech development or better motor skills [11].

The Diagnostic Journey

Confirming an AS diagnosis involves a step-by-step testing process:

  • Step 1: DNA Methylation Testing (MS-MLPA or MS-PCR): This is the first line of defense. It checks the “imprinting” on chromosome 15 and can identify roughly 80% of cases, including deletions, UPD, and imprinting defects [12][13].
  • Step 2: UBE3A Sequencing: If the methylation test is normal but symptoms still point to AS, doctors will sequence the UBE3A gene itself to look for specific mutations [14][15].
  • The Role of EEG: An EEG (electroencephalogram) is a non-invasive test that measures electrical activity in the brain. In AS, the EEG often shows a very specific signature: high-amplitude, slow-frequency waves known as delta power [16][4]. This pattern is so unique that it acts as a biomarker, helping doctors strongly suspect the diagnosis and guide clinical management even before genetic results are finalized [17].

Hope Through “Unsilencing”

Modern research is focusing on a breakthrough idea: if we can stop the “blocker” (UBE3A-ATS) on the father’s copy, we can “unsilence” it and restore the missing protein [18][19]. This is the basis for therapies like Antisense Oligonucleotides (ASOs), which are currently being studied in clinical trials [20][19].

Frequently Asked Questions

What causes Angelman syndrome?
Angelman syndrome is caused by a missing or non-functioning UBE3A gene on the maternal copy of chromosome 15. Because the father's copy of this gene is naturally silenced in the brain, losing the mother's copy means the brain produces no active UBE3A protein, which is essential for typical development.
What are the different genetic subtypes of Angelman syndrome?
There are four main genetic subtypes: maternal deletion, UBE3A mutation, paternal uniparental disomy (UPD), and an imprinting defect. The specific subtype can influence the severity of a child's symptoms, with maternal deletion usually causing the most significant effects.
How is Angelman syndrome diagnosed?
Diagnosis usually begins with DNA methylation testing, which identifies about 80% of cases. If this test is normal but symptoms strongly suggest the condition, doctors will sequence the UBE3A gene to look for specific mutations.
Why do doctors use an EEG to help diagnose Angelman syndrome?
An EEG measures brain waves and can detect a specific electrical signature called delta power that is characteristic of Angelman syndrome. This unique pattern helps doctors strongly suspect the diagnosis and manage potential seizures even before genetic testing is complete.
Are there treatments being developed that target the UBE3A gene?
Yes, researchers are developing therapies like Antisense Oligonucleotides (ASOs) that aim to 'unsilence' the father's copy of the UBE3A gene. If successful, this could restore the missing protein in the brain and treat the underlying cause of the condition.

Questions for Your Doctor

  • • Which of the four genetic subtypes does my child have, and what does that mean for their developmental outlook?
  • • Can you explain the results of the DNA methylation test (MS-MLPA) and whether we need to follow up with UBE3A sequencing?
  • • Does my child's video EEG show the characteristic 'delta wave' pattern, and how does this affect our approach to managing potential seizures?
  • • Is my child's specific genetic mutation 'de novo' (random), or is there a risk of recurrence in future pregnancies?
  • • Are there specific clinical trials for ASO or gene-modifying therapies that my child might eventually qualify for based on their subtype?

Questions for You

  • • What was the 'diagnostic journey' like for us, and what questions remain unanswered about my child's genetic report?
  • • How am I processing the news of the genetic subtype, and do I have a support network to talk through the long-term implications?
  • • Have I noticed any specific 'jerky' movements or unique communication styles that I should bring up during the next neurology appointment?
  • • What are my biggest concerns regarding my child’s future independence and quality of life?

Want personalized information?

Type your question below to get evidence-based answers tailored to your situation.

References

  1. 1

    Caregiving Burden and Quality of Life Among Parents of Individuals With Angelman Syndrome: Gender Differences and the Impact of Financial Well-Being.

    Walkowiak D, Domaradzki J

    Pediatric neurology 2025; (169()):31-39 doi:10.1016/j.pediatrneurol.2025.05.005.

    PMID: 40449417
  2. 2

    A bipartite boundary element restricts UBE3A imprinting to mature neurons.

    Hsiao JS, Germain ND, Wilderman A, et al.

    Proceedings of the National Academy of Sciences of the United States of America 2019; (116(6)):2181-2186 doi:10.1073/pnas.1815279116.

    PMID: 30674673
  3. 3

    A placebo-controlled trial of folic acid and betaine in identical twins with Angelman syndrome.

    Han J, Bichell TJ, Golden S, et al.

    Orphanet journal of rare diseases 2019; (14(1)):232 doi:10.1186/s13023-019-1216-0.

    PMID: 31640736
  4. 4

    Antisense oligonucleotide therapy rescues disturbed brain rhythms and sleep in juvenile and adult mouse models of Angelman syndrome.

    Lee D, Chen W, Kaku HN, et al.

    eLife 2023; (12()).

    PMID: 36594817
  5. 5

    AAV-dCas9 vector unsilences paternal Ube3a in neurons by impeding Ube3a-ATS transcription.

    Wolter JM, James LM, Boeshore SL, et al.

    Communications biology 2025; (8(1)):1332 doi:10.1038/s42003-025-08794-2.

    PMID: 40897812
  6. 6

    An Analysis of Phenotype and Genotype in a Large Cohort of Chinese Children with Angelman Syndrome.

    Du X, Wang J, Li S, et al.

    Genes 2022; (13(8)) doi:10.3390/genes13081447.

    PMID: 36011358
  7. 7

    Angelman syndrome in Poland: current diagnosis and therapy status-the caregiver perspective: a questionnaire study.

    Suleja A, Milska-Musa K, Przysło Ł, et al.

    Orphanet journal of rare diseases 2024; (19(1)):306 doi:10.1186/s13023-024-03292-w.

    PMID: 39174987
  8. 8

    Genotype-Phenotype Correlations in Angelman Syndrome.

    Yang L, Shu X, Mao S, et al.

    Genes 2021; (12(7)) doi:10.3390/genes12070987.

    PMID: 34203304
  9. 9

    Angelman syndrome genotypes manifest varying degrees of clinical severity and developmental impairment.

    Keute M, Miller MT, Krishnan ML, et al.

    Molecular psychiatry 2021; (26(7)):3625-3633 doi:10.1038/s41380-020-0858-6.

    PMID: 32792659
  10. 10

    Assessment of Dysphagia in Chinese Cohort of Angelman Syndrome: An Observational Study.

    Chen Y, Wang Y, Zhang Y, et al.

    CNS neuroscience & therapeutics 2025; (31(8)):e70587 doi:10.1111/cns.70587.

    PMID: 40852931
  11. 11

    Atypical Angelman syndrome due to a mosaic imprinting defect: Case reports and review of the literature.

    Le Fevre A, Beygo J, Silveira C, et al.

    American journal of medical genetics. Part A 2017; (173(3)):753-757 doi:10.1002/ajmg.a.38072.

    PMID: 28211971
  12. 12

    Clinical Utility of Methylation-Specific Multiplex Ligation-Dependent Probe Amplification for the Diagnosis of Prader-Willi Syndrome and Angelman Syndrome.

    Kim B, Park Y, Cho SI, et al.

    Annals of laboratory medicine 2022; (42(1)):79-88 doi:10.3343/alm.2022.42.1.79.

    PMID: 34374352
  13. 13

    Diagnosis of Prader-Willi syndrome and Angelman syndrome by targeted nanopore long-read sequencing.

    Yamada M, Okuno H, Okamoto N, et al.

    European journal of medical genetics 2023; (66(2)):104690 doi:10.1016/j.ejmg.2022.104690.

    PMID: 36587803
  14. 14

    Novel intragenic deletions within the UBE3A gene in two unrelated patients with Angelman syndrome: case report and review of the literature.

    Aguilera C, Viñas-Jornet M, Baena N, et al.

    BMC medical genetics 2017; (18(1)):137 doi:10.1186/s12881-017-0500-x.

    PMID: 29162042
  15. 15

    The role of whole exome sequencing in the UBE3A point mutation of Angelman Syndrome: A case report.

    Triono A, Iskandar K, Nugrahanto AP, et al.

    Annals of medicine and surgery (2012) 2022; (73()):103170 doi:10.1016/j.amsu.2021.103170.

    PMID: 34976390
  16. 16

    Longitudinal EEG model detects antisense oligonucleotide treatment effect and increased UBE3A in Angelman syndrome.

    Spencer ER, Shi W, Komorowski RW, et al.

    Brain communications 2022; (4(3)):fcac106 doi:10.1093/braincomms/fcac106.

    PMID: 35611307
  17. 17

    Evaluation of electroencephalography biomarkers for Angelman syndrome during overnight sleep.

    Levin Y, Hosamane NS, McNair TE, et al.

    Autism research : official journal of the International Society for Autism Research 2022; (15(6)):1031-1042 doi:10.1002/aur.2709.

    PMID: 35304979
  18. 18

    Therapies in preclinical and clinical development for Angelman syndrome.

    Markati T, Duis J, Servais L

    Expert opinion on investigational drugs 2021; (30(7)):709-720 doi:10.1080/13543784.2021.1939674.

    PMID: 34112038
  19. 19

    An ASO therapy for Angelman syndrome that targets an evolutionarily conserved region at the start of the UBE3A-AS transcript.

    Dindot SV, Christian S, Murphy WJ, et al.

    Science translational medicine 2023; (15(688)):eabf4077 doi:10.1126/scitranslmed.abf4077.

    PMID: 36947593
  20. 20

    Angelman syndrome patient-derived neuron screen leads to clinical ASO rugonersen targeting UBE3A-ATS with long-lasting effect in monkeys.

    Jagasia R, Bon C, Rasmussen SV, et al.

    Nucleic acids research 2025; (53(16)) doi:10.1093/nar/gkaf851.

    PMID: 40884397

This page explains the genetics and diagnosis of Angelman syndrome for educational purposes only. Always consult a pediatric neurologist or geneticist to interpret your child's specific genetic report and medical needs.

Stay up to date

Get notified when new research about Angelman syndrome is published.

No spam. Unsubscribe anytime.